Discovering and developing a cancer drug that can treat many types of the disease can be extremely lucrative. Consider that one such drug, Merck’s (NYSE:MRK) Keytruda, generated $25 billion in revenue for the pharmaceutical giant last year. And even back in 2018, its fourth year on the market, the drug was responsible for putting $7.2 billion in Merck’s coffers. Many new types of cancer treatments are being developed, including personalized cancer vaccines, and precision oncology treatments. But very few treatments have the potential to be the next Keytruda. In this column on cancer treatment stocks, I will identify two companies with drugs that I think could fit the bill. I will also profile a company that has developed a blood test which successfully detects many types of the disease in the early stages. By doing so, it can save millions of lives. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Grail (GRAL) Grail sign at its headquarters in Menlo Park, California, USA, June 11, 2023. Grail is an American biotechnology company. GRAL stock Source: JHVEPhoto / Shutterstock.com Grail’s (NASDAQ:GRAL) Galleri blood test can determine whether individuals have over 50 types of cancer. Moreover, the diagnostic can show, with nearly 90% accuracy, where the cancer is located. And according to Grail, the test has a very low false positive rate of just 0.5%. The test can save millions of lives by identifying asymptomatic cancer cases before they become impossible to treat. For example, by the time people with pancreatic cancer show symptoms, it’s generally after their cancer has spread beyond the initial tumor. Consequently, the vast majority of people with the disease die from it. But if pancreatic cancer is discovered while it’s still localized to the pancreas, the five year survival rate is 44%, compared to just 3% for patients diagnosed in the latest stages of disease. Although the vast majority of insurers have not yet been willing to cover Grail’s test, I believe that they will ultimately do so. That’s because, given the fact that cancer costs the U.S. $200 billion annually, there’s a large economic incentive to lower that figure. That’s particularly true for private insurers, governments, and hospitals that bear the lion’s share of those costs. Moreover, once word spreads among the public of the fact that their lives can easily be saved by Grail’s test, political pressure to cover its diagnostic tool should mount. ImmunityBio (IBRX) A scientist holding up her biotech experiment in a small Petri dish. Source: Shutterstock Experts estimate that ImmunityBio’s (NASDAQ:IBRX) Anktiva biologic, which has been approved as a treatment for nonmuscle invasive bladder cancer, can generate $878 million as a treatment for that indication in 2028. Also positively, on June 20, the company reported that multiple insurers had agreed to cover the drug for these patients. Additionally on April 25, the company disclosed that, in a Phase 3 trial, non-small cell lung cancer (NSCLC) patients who took the drug had “median overall survival almost double that of standard of care chemotherapy.” The company noted that it had scheduled a meeting with the Food and Drug Administration to discuss submitting an application for the approval of the drug as a treatment for “2nd– and 3rd-line NSCLC patients whose cancer previously did not respond to checkpoint therapy.” ImmunityBio believes that 80%-85% of the over 238,000 of estimated lung cancer cases in the U.S. were in the NSCLC category. Hypothetically, if 50% of lung cancer patients are treated with Anktiva and the company charges the same $216,000 per patient (six doses at $36,000 per dose) that it’s seeking for bladder cancer patients, that would work out to $25.7 billion of annual revenue for the company from the NSCLC category alone. Moreover, ImmnityBio has reported that Anktiva shows promise for treating pancreatic cancer as well. Given the huge potential of Anktiva, I view ImmunityBio as one of the best cancer treatment stocks to buy. GSK (GSK) A GlaxoSmithKline (GSK) office in London. Source: Willy Barton / Shutterstock.com GSK’s (NYSE:GSK) Jemperli treatment continues to make progress towards becoming a very lucrative, highly successful treatment for multiple types of cancer. On July 1, the European Medicines Agency, the EU’s version of the FDA, agreed to evaluate an application by GSK to allow the drug to be used to “treat all adult patients with primary advanced or recurrent endometrial cancer.” The company expects its application to be approved in the first half of 2025. The drug was previously approved by the EMA to treat only some patients with advanced or recurrent endometrial cancer. About 417,000 cases of new endometrial cancer are reported annually on a global basis. And approximately 121,000 people are estimated to be “diagnosed with primary advanced or recurrent endometrial cancer yearly in Europe,” BioPharmInternational.com reported. Similarly, in April the FDA agreed to consider approving Jemperli for use by the same group of patients in the U.S. The agency is expected to make a decision on the application next month. As is the case in the EU, Jemperli is only currently approved for some patients with primary advanced or recurrent endometrial cancer. An estimated total of nearly 68,000 cases of endometrial cancer will be diagnosed in the U.S. this year, according to the American Cancer Society. Meanwhile, in June GSK reported that a Phase 2 study of Jemperli as a treatment for rectal cancer continues to show that the 42 patients who took the drug were basically completely cured. In more technical terms, an unprecedent 100% of patients had a “complete pathologic response or no evidence of tumors” as assessed by a number of tests. Nearly one-third of patients who receive standard-of-care treatment for rectal cancer die from the disease , according to GSK. What’s more, the standard of care, unlike Jemperli, often causes severe, long-term side effects. On the date of publication, Larry Ramer held long positions in GRAL and IBRX. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines. On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article. Larry Ramer has conducted research and written articles on U.S. stocks for 15 years. He has been employed by The Fly and Israel’s largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been SMCI, INTC, and MGM. You can reach him on Stocktwits at @larryramer. More From InvestorPlace Legendary Investor Predicts: “Forget AI... THIS Technology Is the Future” The post 3 Top Cancer Treatment Stocks to Buy Now appeared first on InvestorPlace.
3 Top Cancer Treatment Stocks to Buy Now
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...